67
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Reliable intraocular pressure measurement using automated radio-wave telemetry

, , , , &
Pages 177-185 | Published online: 07 Jan 2014

Figures & data

Figure 1 Schematic diagram of the wireless IOP acquisition technique.

Notes: A motion sensor (left) is used to trigger measurements each time the rabbit drinks from the water bottle (center). A wireless coil antenna (right), placed next to the eye with the implanted transducer, measures the IOP each time the motion sensor triggers a signal. All parts are housed in a polymethylmethacrylate box for protection and arranged in a way to optimize the quality of the signal. This technique provides autonomous IOP measurements, avoiding animal stress from human interaction and thus artificial IOP aberrations.
Abbreviation: IOP, intraocular pressure.
Figure 1 Schematic diagram of the wireless IOP acquisition technique.

Figure 2 Circadian IOP variation with (A) latanoprost, (B) dorzolamide, and (C) vehicle administration.

Notes: The data points represent independent IOP measurements during 2 weeks of measurements. The dotted black line represents the polynomial fit (5th order) of the data set and the two red lines is the boundary between 1 ± standard deviation from IOP mean.
Abbreviations: H, hours; IOP, intraocular pressure; M, minutes.
Figure 2 Circadian IOP variation with (A) latanoprost, (B) dorzolamide, and (C) vehicle administration.

Figure 3 Diurnal and nocturnal IOP reduction with latanoprost and dorzolamide.

Notes: No difference between diurnal and nocturnal IOP with latanoprost (P.0.318) or dorzolamide (P>0.683). However, latanoprost causes significantly higher IOP reduction that dorzolamide in both diurnal (P<0.003) and nocturnal (P<0.002) IOP measurements. *Statistically significant difference compared to baseline IOP (t-test).
Abbreviations: IOP, intraocular pressure; NS, nonstatistically significant difference (t-test); CI, confidence interval.
Figure 3 Diurnal and nocturnal IOP reduction with latanoprost and dorzolamide.

Table 1 IOP reduction with placebo, latanoprost 0.005%, and dorzolamide 2% compared to baseline